Vitamin C tablets

Pays: Arménie

Langue: anglais

Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Ingrédients actifs:

ascorbic acid

Disponible depuis:

Arpimed LLC

Code ATC:

A11GA01

DCI (Dénomination commune internationale):

ascorbic acid

Dosage:

250mg

forme pharmaceutique:

tablets

Unités en paquet:

(10/1x10/) in blister

Type d'ordonnance:

OTC

Statut de autorisation:

Registered

Date de l'autorisation:

2020-05-01

Résumé des caractéristiques du produit

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT
Vitamin C 250 mg tablets
Vitamin C 500 mg tablets
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 250mg of ascorbic acid.
Each tablet contains 500mg of ascorbic acid.
For excipients, see 6.1.
3. PHARMACEUTICAL FORM
Tablet
250mg tablets: round biconvex white tablets scored on one side;
without odor
500mg tablets:
slightly violet round biconvex tablets of white color;
without odor
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Prevention and treatment of scurvy.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Route of administration:
Oral
Dose
Adults (including the elderly) and children over 6 years:
_ _
_Prophylactic:_ 25 – 75 mg daily.
Note: Thеsе unit dosages forms аre unsuitable for prophylactic use.
_Therapeutic: _Not less than 250mg daily in divided doses.
Maximum of
1000mg daily.
Children under 6 years:
These unit dosage forms are unsuitable for children under 6 years.
4.3 CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.
Ascorbic acid should not be given to patients with hyperoxaluria.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Increased intake of ascorbic acid over a prolonged period may result
in an increase in renal
clearance of ascorbic acid and deficiency may result if it is
withdrawn rapidly (see section 4.8).
Interference with serological testing
Ascorbic acid may interfere with tests and assays for urinary glucose,
giving false-negative
results with methods utilising glucose oxidase with indicator (e.g.
Labstix, Tes-Tape) and false-
positive results with neocuproine methods.
Estimation of uric acid by phosphotungstate or uricase with copper
reduction and measurement
of creatinine in non-deproteinised serum may also be affected.
High doses of ascorbic acid may give false-negative readings in faecal
occult blood tests.
Patients with rare hereditary problems of galactose intolerance, total
lactase deficiency or
glucose-galactose malabsorption should not